The involvement of major histocompatibility complex (MHC) antigens in the development and regulation of immune response has been well defined over the years, starting from maturation, antigenic peptide loading, migration to the cell membrane for recognition by the T-cell receptor and recycling for immune response cessation. During this intracellular trafficking, MHC antigens find a way to be excreted by the cells, because they can be found as soluble MHC class I (sMHC-I) and class II (sMHC-II) molecules in all body fluids. Although secretion mechanisms have not been sufficiently studied, sMHC molecules have been shown to display important immunoregulatory properties. Their levels in the serum have been shown to be altered in a variety of diseases, including viral infections, inflammation, autoimmunities and cancer, etc. while they seem to be involved in a number of physiological reactions, including maintenance of tolerance, reproduction, as well as mate choice vis-a-vis species evolution. The present review aims to present the thus far existing literature on sMHC molecules and point out the importance of these molecules in the maintenance of immune homeostasis.
Introduction
Major histocompatibility complex (MHC) molecules have been defined as cell surface proteins loaded with antigenic peptides and recognized by the T-cell receptor (TCR) on T-cells, to initiate or propagate acquired immunity.
Class I molecules were initially described to be responsible for rapid graft rejection in mice, while class II MHC molecules were identified as the products of immune response (Ir) genes, which dictate the ability of an organism to respond to specific antigenic stimuli. 1 The inheritance of such polymorphic traits is linked to the histocompatibility genes of H-2 in mice and human leucocyte antigens (HLA) in humans, located on chromosomes 17 and 6, respectively.
Histocompatibility loci, especially in mice and humans, have been the subject of extensive studies for the last 50 years, revealing multiple, complex and highly regulated structures, responsible for all immune system defense mechanisms. Closely located genes encode for polymorphic and non-polymorphic proteins involved in the antigen presentation process of class I and class II MHC molecules, as well as various effector molecules of the immune response (Fig. 1) . Thus, MHC loci include polymorphic elements assembled to provide the personalized histocompatibility, and non-polymorphic genes, which are necessary to immune processes.
With regard to class I family in humans, the classical A, B and C genes at the telomeric region of chromosome 6 consist of highly polymorphic counterparts, including more than 12 000 alleles, while the non-classical E, G and F genes are much less polymorphic, represented by approximately 100 different alleles. 2 Mature class I protein is a heterodimer, consisting of the HLA-encoded
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gene product (heavy chain), assembled with the monomorphic b2-microglobulin encoded by chromosome 15 (light chain) in the endoplasmic reticulum (ER), which upon binding to an antigenic peptide is transferred through the Golgi system to the cellular membrane. Antigen-loaded MHC-I molecules are recognized by CD8 + T cytotoxic cells and become their target for apoptotic cell killing.
The class II family of proteins is more complicated, as classical DP, DQ, DR heterodimers are encoded by six polymorphic genes resulting in more than 20 000 different allelic combinations. By the same token, non-classical DM and DO genes are less polymorphic, represented so far by approximately 250 different alleles. Classical as well as non-classical MHC class II (MHC-II) antigens are transmembrane dimeric molecules consisting of a (~35 kDa) and b (~28 kDa) chains, the difference of the size due mainly to the variance of N-linked glycosylations. 3 In classical MHC-II proteins the outer-membrane part of the molecule forms a groove for the peptide, which upon binding ensures the highest stability of the molecule. 4 Upon synthesis, classical MHC-II a and b chains associate in the ER with the invariant chain (Ii; CD74) into nonameric complexes (abIi) 3 and transported to the endosomal compartments for antigen loading. 5 Within the endosomal compartments the Ii protein is submitted to sequential proteolysis from the laminar side, leaving the final class II-associated Ii peptide (CLIP) in the binding site of MHC-II. 6 The release of CLIP is catalyzed by the non-classical HLA-DM molecules, which are present in all antigen-presenting cells (APCs), are lysosomal-resistant, show limited polymorphism and do not bind antigenic peptides. 7, 8 Antigen-loaded MHC-II molecules are thereafter transported to the cell membrane for recognition by CD4 + cells.
All these steps of MHC maturation are heavily regulated. The presence of additional positive and negative regulators, the existence of different CD74 isoforms, mechanisms of cross-presentation, alter MHC trafficking within the intracellular compartments and affect the antigen presentation process. In addition, phosphorylations, ubiquitinations, sumoylations and glycosylations evoke different behaviours of the above-described molecules. 9 The CD4 + subpopulation of T-cells plays the central role in immune function. Recognition of the complex MHC-II antigen occurs through TCR, and depending on the presence and nature of costimulatory molecules, T-cells will respond with production of stimulatory or suppressive factors. When T-cells recognize the complex MHC-II-antigen on the surface on an APC, the costimulatory molecules exert their effect through ligand recognition on the APC. The CD28/cytotoxic T lymphocyte antigen-4 (CTLA-4) is, so far, the best understood costimulatory pathway. 10, 11 Thus, CD28 has been considered to promote the initiation of T-cell responses, whereas CTLA-4 has been shown to down-regulate the immune response. The preferential recruitment of CTLA-4 for B7Á1 and CD28 for B7Á2 12 suggested that the tuning of the immune response depends on the relative levels of B7Á1/B7Á2 expressed on APCs.
Binding of TCR to the MHC-II antigen complex initiates chain reactions leading to specific gene activation. Thus, recognition of the MHC-II antigen complex by TCR recruits CD4, which stabilizes binding through specific contact points with MHC-II molecules and activates the p56lck kinase which, in turn, by phosphorylating tyrosine residues present in the immunoreceptor tyrosine-based activation motif (ITAM) motifs of the CD3-f complexes attracts the cytosolic ZAP70 kinase on phosphorylated ITAM motifs which is also activated by a p56lck-dependent phosphorylation (Fig. 2) . One of the substrates of phosphorylated ZAP70 is the L-type amino acid transporter (LAT), which will continue the chain reaction until nuclear factor kappa B (NF-jB) activation. 13 Although MHC molecules are generally considered to be transmembrane cell surface proteins, soluble MHC (sMHC) antigens are detected in almost all body fluids, yet their role and origin are still unclear. The present review attempted to gather information as to the biochemistry, function and role of sMHC antigens with particular interest to sMHC class II (sMHC-II) molecules.
Historical background
In early 1967 Calne and his co-workers observed that one of the 19 liver-transplanted pigs survived for 7 months after receiving the allograft without any immunosuppressive treatment and finally died from intestine disorders.
14 Two years later a more extensive study was published, showing that long-term pig survival after liver allogeneic transplant was a common phenomenon. Animals developing tolerance to the liver allograft were also tolerant to other donor organs. In order to explain these observations, the authors had hypothesized that the allogeneic liver secreted tolerogenic elements, which remained in recipient blood circulation as long as transplant was functional and ceased to exist, when liver transplant was removed or rejected by the recipient. 15 These factors were identified to be sMHC molecules. 16 Thereafter, many laboratories attempted to define the immunoregulatory effects of various soluble forms of MHC molecules. High concentrations of soluble HLA were detected in urine samples of patients with renal disorders compared to healthy individuals. 17 However, detection methodologies at that time were not consistent and were unable to detect low concentrations. Radio-labelled polyclonal anti-HLA antibodies were used to inhibit and study HLA serum activity 18 or detect soluble HLA molecules in cell culture supernatants. 19 The development of enzymelinked immunoassays was thereafter used to quantify sMHC-I 20 and sMHC-II proteins. 21 Today, it is widely accepted that body fluids isolated from healthy individuals contain various amounts of sMHC molecules. 16, 22, 23 Reported levels of sHLA-DR in sera of healthy donors vary significantly from 0Á31 ng/ 24 to 1400 ng/ml. 23 Other studies place that range from 0Á02 ng/ml 24 to 100 ng/ml. 25 Such variations, however, are possibly due to the use of different monoclonal antibodies or cross-reactivity with other serum proteins. Regardless of the physiological levels of sMHC-II proteins in the serum of healthy individuals, many pathological conditions including viral encephalitis, 22 rheumatoid arthritis, 26 pathological pregnancies, 23, 24 asthma, 27 AIDS, 22 chronic hepatitis C and acute chronic uveitis 28 have been shown divergence of sMHC-II levels from control values. By the same token, the reported levels of sHLA-I in healthy individuals vary from 357 ng/ml 20 to 1Á06 lg/ml, 29 while they significantly increase in AIDS patients, 29 as well as in cases of rheumatoid arthritis, systemic lupus erythematosus (SLE), Sjogren's syndrome and multiple sclerosis (MS). [30] [31] [32] [33] [34] [35] Structure and origin of sMHC molecules
In 1973, Miyakawa et al. studied the heterogeneous isoforms of sMHC-I proteins in human plasma using polyclonal anti-serum and detected two polypeptide chains. The first displayed a molecular weight of 48 kDa and appeared to be similar to the membrane HLA-I protein that had sustained papain proteolysis. The second polypeptide chain showed a molecular weight of 80 kDa that was reduced to 48 kDa after papain treatment. 19 Kubens et al. 36 could also detect two polypeptide chains but at 33 and 12 kDa, which were identified to correspond to the HLA-I heavy chain and b2-microglobulin, respectively. Further studies showed that serum sMHC molecules share the same molecular weight with sMHC molecules isolated from urine. 37 When human plasma was examined by Western blot analysis, three isoforms of sMHC-I were found at 44, 40 and 37-35 kDa. The larger molecule included a transmembrane fragment and a cytoplasmic tail; the 40 kDa polypeptide had only a transmembrane fragment, probably due to alternative splicing, 38 also confirmed by polymerase chain reaction (PCR) techniques and DNA sequencing, 39 while the smallest isoform lacked both transmembrane and cytoplasmic fragments. 40 Special attention has been given over the years on the non-classical sHLA-G which, however, will not be discussed in the present review.
Studies on sMHC-II report either a 60-kDa heterodimer or single polypeptide molecule (HLA-DR), which showed higher molecular weight compared to membrane surface proteins 41, 42 or dimers of 28 and 43 kDa with similar patterns in serum and saliva. 22 Soluble MHC-II proteins have been shown to carry an antigenic load. 12, 42, 43 Today, it is widely accepted that all body fluids (blood, saliva, semen, tears, urine and sweat) contain various amounts of sMHC-I and -II. 16, 22, 23 Aultman et al.
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showed that sMHC-I are mainly located in blood serum and are not detectable in saliva, sweat and tears, while sMHC-ΙΙ are found in all body fluids at significant amounts. Later it was confirmed that the physiological distribution of sMHC-I was different from that of sMHC-II and that their concentration was considerably lower. 44 The origin of these molecules has been hypothesized to be the result of shedding, alternative splicing or active secretion. In case of the non-classical HLA-G, the different isoforms, including the soluble one, have been shown to involve indeed alternative splicing, 39 but this is the only example known so far. Liver appears to be an important source of sMHC-I, thus explaining why acute organ rejection is somewhat unusual in liver transplants. On the contrary, the exact mechanisms of sMHC-II secretion remain unknown, probably because little is known about their structure. Recently, Bakela et al. showed that sMHC-II molecules isolated from human serum albumin (HSA)-tolerant mice demonstrate incredible stability, as all efforts to dissociate the heterodimer, including different time-points of boiling at 95°, up to 8 M urea or high salt concentration treatments, failed to separate the a and b chains of the molecules, as previously described. In this study, sMHC-II were found to be highly glycosylated 41, 42 while mass spectroscopy analysis (MS-MS) detected the presence of the H-2Ab chain. 42 Many in-vitro studies show that APCs, mainly B-cells and leukaemia cells, secrete exosomes that contain large amounts of MHC molecules. 45, 46 Other studies have demonstrated that trophoblasts secrete in culture medium sMHC-II molecules when stimulated by interferon (IFN)-c. 47, 48 In addition, upon interleukin (IL)-2 activation, Band CD4
+ T-cells secrete large amounts of sMHC-II proteins, while in the presence of macrophages T-cells secrete four times higher amounts. 41 However, serum sMHC molecules have been shown not to be associated with exosomes. 45 In such cases it could be hypothesized that sMHC-II were associated with exosomes when secreted from the cells, which were thereafter degraded in blood. However, further studies are required to clarify this issue, because exosomes are quite sensitive to handling conditions 49 and can therefore mislead the interpretation of results.
Function of sMHC molecules
Soluble MHC molecules have been related to immune tolerance. If transfused in engrafted recipients, sMHC-I proteins display immunosuppressive activities in graft rejection. 50, 51 In fact, it was shown that sMHC-I antigens isolated from liver were able to suppress humoral and, to a smaller degree, cellular responses. 52, 53 There are also several studies suggesting that HLA-I derived peptides induce tolerance or suppression of immune responses. negatively regulated and submitted to apoptosis by sMHC-I. 55, 56 Conversely, sMHC-I could activate CD8 + Τ-cells 57 and induce apoptosis in alloreactive cytotoxic T-cells. 58 Kress et al. 59 have identified a gene related to MHC-I in murine liver, which was produced as secreted transplantation antigen and hypothesized to be related to self-tolerance.
Although soluble and membrane forms of MHC-II molecules may share common structural features, 41 recent studies indicate that sMHC-II compete with membrane MHC-II vis-a-vis TCR binding on CD4 + T-cells, resulting in inhibition of the immune response. 60 Therefore sMHC molecules can bind to their natural receptors and suppress T-cells through apoptosis or receptor blockage.
Soluble MHC-II proteins have been shown to carry an antigenic load. In such cases, self-antigens should display a suppressive activity to ensure self-tolerance maintenance. 12, 43 Recently, MS-MS analysis of serum purified sMHC-II molecules, isolated from HSA-tolerant mice, revealed a large number of self-peptides, indicating that they were indeed loaded with the tolerogenic peptide (HSA), as well as with an abundance of self-peptides. 42 Other studies indicate that CD4 + T-cells isolated from tolerant mice secrete tolerosomes in serum that are MHC-dependent. 61 This observation was further supported by studies showing that exosome mediated tolerance is MHC-II-dependent. 62 During the 1970s and 1980s T-suppressors were suggested to exert their effect via suppressor factors bearing class II MHC determinants. 63 Soluble MHC-II molecules, isolated from the serum of BALB/c mice, have been shown to display important immunomodulatory properties. 60 Thus, sMHC-II were shown to stimulate spleen cell proliferation and the major target was identified to be the CD4 + cell population. Inhibition of the CD4 co-receptor using specific neutralizing antibodies destroyed the sMHC-II-mediated proliferative activity, while sMHC-II successfully antagonized surface IA d antigens for binding to anti-IA d antibody. Serum sMHC-II (sIA d ) stimulated BALB/c versus C3H/HeN but not C3H/HeN versus BALB/c mixed lymphocyte reactions, while increasing responsiveness to Legionella pneumophila. However, sMHC-II displayed an inhibitory activity during the effector phase of the humoral response, as they inhibited the anti-dinitrophenylated (DNP)-specific immunoglobulin (Ig)M production to a DNP-HSA hapten-carrier system. Furthermore, sMHC-II molecules increased T helper type 1 (Th1)/Th2 cytokines during the L. pneumophila stimulus, while decreasing IL-2, granulocyte-macrophage colony-stimulating factor (GM-CSF) and increasing IL-4 and IL-15 during the DNP-HSA stimulus. 60 These results suggested that sMHC-II could compete with surface MHC-II molecules and inhibit the effector phase of humoral or cellular immune responses. 64 Thus, it appears that sMHC-II may induce both positive and negative signals, apparently depending on their antigenic load and their cellular target. Self-antigens promote a suppressive activity to reassure self-tolerance. 10, 43 Antigenspecific tolerogenic stimulation was shown to increase serum MHC-II proteins when compared to the immunogenic stimulus in mice in vitro as well as in vivo. 65 Thus, the concentration of sMHC-II molecules isolated from HSAtolerant mice was four times higher than sMHC-II isolated from control mouse serum. 42 At the physiological level, sMHC-II proteins were shown to suppress not only an antigen-specific but also antigen non-specific immune activation. In addition, they could increase CD25 expression on naive CD4
+ cells and decrease CD28, while increasing CTLA expression. 42 In the same study, sMHC-II decreased IL-2 while increasing IL-10 production, which could account for another mechanism of non-specific suppression. Finally, these molecules inhibited phosphorylation of ZAP-70 and especially LAT proteins in the downstream pathways of TCR signalling in CD4 + cells. 42 
sMHC in health and disease
As already mentioned, sMHC are being detected in all body fluids of healthy individuals. Although information regarding the physiological levels of these molecules in the different fluids is not definitely available, many studies compare sMHC levels in various pathological conditions and conclude their role in disease diagnosis, development and treatment. In several human pathologies and experimental mouse models, lower levels of sMHC-II have been detected in the serum as compared to healthy controls. 66 Regarding mouse models, sMHC-II levels declined in the serum as the tumour was growing, which was also verified in humans in cases of gastric cancer. 67 Moreover, liver malignant patients had lower levels of sMHC-I in comparison to patients with other liver diseases. 68 Soluble MHC-II proteins seem to be closely related to certain types of leukaemia. Elevated concentrations of sMHC-II (sHLA-DR) were observed in patients with acute lymphoblastoid leukaemia compared to those that had developed acute myeloid leukaemia 69 or chronic lymphocyte leukaemia. 21 Finally, melanoma patients at late stages of the disease show decreased levels of sMHC-II, possibly due to the reduced immune system function. 70 Changes within the physiological concentrations of sMHC molecules have been recorded in numerous pathological conditions, such as viral encephalitis, 22 rheumatoid arthritis, 26 pathological pregnancies, 23, 24 asthma, 27 chronic iris inflammation 28 and AIDS. 22 In familial endometriosis, reduced levels of serum-sMHC molecules have been detected compared with healthy subjects.
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Serum sMHC-I levels were found to be elevated in chronic hepatitis, where it was correlated with the increase of serum glutamate transaminase, 72 as well as in active pulmonary tuberculosis. 73 Elevated concentrations have also been observed during haemorrhagic fever in patients with renal syndromes, 74 in children with severe atopic dermatitis 75 and in varicella-zoster virus meningitis-infected patients who showed increased sMHC levels not only in serum but also the cerebrospinal fluid (CSF). 76 In addition, it has been postulated that sMHC proteins play an important immunoregulatory role during allogeneic blood transfusions. 77 Serum sMHC-II levels were described to be increased in AIDS patients. 78 In this case serum sMHC-I levels were also found to be three times higher compared to healthy volunteers, 29 while elevated concentrations were also detected in CSF. 79 These levels were correlated with the stage of the disease, and it was hypothesized that these molecules play an important role in the development of immune suppression in AIDS patients, 80 ,81 thus anticipating their inability to respond to HIV-I.
Special attention is given to autoimmunities. Rheumatoid arthritis, SLE, MS and Sjogren's syndrome have been thoroughly studied in regard to sMHC molecules. Soluble MHC-I proteins have been reported to be highly elevated in patients with RA, SLE and Sjogren's syndrome, [30] [31] [32] [33] [34] while sMHC-II have also been observed in synovial fluid of RA patients. 82 In this case, sMHC-II levels were found to increase with RA progression and reduce during treatment. The combination of methotrexate and prednisolone, except from symptom alleviation, also reduced the levels of sMHC-II, possibly due to blockage of secretion mechanisms. 26 Alterations of sMHC levels have also been described in the CSF of MS patients, 35 and correlated with the proper function of the central nervous system. 83 However, it is important to understand the mechanisms of sMHC action and their interference with immune regulation. It has been shown that sMHC-II can induce long-term tolerance in alloreactive acetylcholine receptor-specific T-cells in myasthenia gravis. 84 In allergic encephalomyelitis experimental murine models, incubation of myelin basic protein autoreactive T-cells with sMHC-II/myelin basic protein (ΜΒΡ) peptide complex resulted in clonal anergy. 85 These results imply that sMHC molecules play an important role in the pathology of these diseases, but it is not yet clarified whether they contribute to the pathology or whether they constitute byproducts of the pathological condition. However, once the physiological levels of these molecules have been determined, they could be used as biomarkers for the development and treatment of various conditions and diseases.
sMHC in reproduction
During pregnancy the levels of sMHC-I and sMHC-II molecules in the serum follow a specific pattern of production depending on the embryonic developmental stage. Thus, sMHC-I have been described to be directly involved with the development of maternal anti-paternal immunosuppression, while sMHC-II were correlated with immune activation. Serum sMHC-I concentrations were shown to be higher during the first two trimesters and decreased during the third trimester, while reaching physiological levels after delivery. 86 Thus, a successful pregnancy outcome requires an equilibrated balance of sMHC protein levels, where increase of sMHC-I and decrease of sMHC-II levels control, among other mechanisms, the development of the immunosuppressive and immunostimulatory state of the mother. 87 This equilibrated profile was shown to be altered in cases of recurrent abortions in humans as well as in experimental mouse models. 88 It has been described both in vitro and in vivo that trophoblasts produce sMHC-II molecules upon IFN-c activation, 89, 90 which could account for the increase of sMHC-II levels during pregnancy. 48 However, increased levels IFN-c resulted in surface membrane expression of MHC-II, which was correlated with fetal loss. 90 Soluble MHC molecules ensure a cross-talk between the mother and the developing fetus. It has been confirmed that maternal sMHC antigens can cross the placental barrier, while fetal soluble sMHC-I molecules could be detected in maternal blood even 8 weeks after conception. 91 In a related study, natural killer (ΝΚ) cells from the umbilical cord blood showed a significantly decreased cytotoxic activity in correlation with adult NK cells, which was correlated with the presence of sMHC antigens in the umbilical cord blood. 92 As mentioned in a previous section, during pregnancy sMHC-II stimulated proliferation of CD25 À CD4 + , CD25 + CD8 + and CD25 + CD4 + cell populations, while inhibiting CD25
À CD8 + cells. 64 It can therefore be mentioned once again that the role of sMHC molecules depends upon their antigenic load and their target.
sMHC in mate choice
Accumulative evidence suggests that sMHC proteins are involved in mate choice. 93 Three major hypotheses attribute MHC polymorphism a central role in evolution, including the increase of resistance to infectious diseases, the ability to provide a 'moving target' against the rapidly evolving parasites and inbreeding avoidance. Ober et al., 94 studying classical HLA in 400 Hutterite couples, found significantly fewer HLA identities than expected, while Chaix et al., 95 after genotyping African and European couples in America, showed that HLA-different partners were favoured. This property of mate choice has been attributed to MHC-dependent molecules, the so-called 'odortypes', through olfactory mechanisms. 93 Odortypes are considered to be sMHC molecules present mainly in the urine 96 and sweat, while it has been considered that the haematopoietic system could be a source of odorants that distinguish major histocompatibility types. 97 Both MHC-I and MHC-ΙI loci have been postulated to contribute the distinction of odortypes. 98 However, it is not clear how MHC could influence body odour, as MHC molecules are relatively large non-volatile proteins. To this extent, three hypotheses have been postulated: (i) MHC molecules specifically bind some volatile compounds and carry them to apocrine glands, (ii) MHC molecules could bind peptides that become volatile during the metabolic process and (iii) MHC molecules might influence symbiotic micro-organisms living on the skin surface. 99 Although the existence of odortypes and their control by MHC molecules is no longer questioned, the mechanisms underlying such events remain unclear.
Future perspectives
Understanding the role of sMHCs is an extremely difficult goal to achieve. It is clear that reference to sMHC-I or sMHC-II does not apply to single identity molecules. sMHC-Is might be the products of the polymorphic A, B, C and the less polymorphic E, F, G genes in humans, the products of K, D, L genes in mice or other as-yet undefined genes in both species. By the same token, sMHC-IIs might be the products of DP, DQ, DR in humans, A and E in mice or other not definitely defined similar genes. Indeed, the MHC locus, both in humans and mice include a large number of the so-called 'pseudogenes', which are being detected at the genomic levels as active genes without, however, corresponding to an identifiable product so far (Fig. 1) . At this point it is useful to refer to the 'I-J paradox'. The initial genetic studies in the 1070s that placed the Ir region between the K and D loci of chromosome 17 included, with the exception of the Aa, Ab, Eb, Ea regions, the B, J, C loci. Among these, I-J was thoroughly studied and was found expressed on T suppressor inducer cells. When the product of the I-J region on Ts was found to be longer than the I-J loci itself, scientists began to doubt its existence, and referred to it as the 'I-J paradox', and its study was slowly abandoned. 80 I-J does not appear in the recent maps of the H-2 locus, but instead other genes with no attributed function are being described.
Most of the studies that describe, detect and isolate sMHC molecules have been using antibodies which recognize the non-polymorphic parts of the molecules, so that they can be universally used within the same species population. Therefore, distinction between the different gene products is difficult to achieve.
Another important parameter is that even if the MHC protein is produced from the same gene, it can be loaded with a variety of antigenic peptides conferring different properties to the molecules vis-a-vis their target TCR and consequently the nature of T-cells bearing those TCRs. This could explain why the same MHC molecule may exert a stimulatory or an inhibitory effect on a T-cell population with the same TCR specificity but different co-receptor expression.
The extreme variance in all MHC-related parameters makes the study of sMHC only superficial, thus explaining the variability of results in the different laboratories. However, it can be generally accepted that membranebound MHCs can compete with sMHCs for the same target and completely alter the expected reaction.
Considering the affinity of binding between MHC/antigen and TCR, one could foresee that MHC molecules loaded with an antigenic epitope A could interact with a B epitope-specific TCR with lower affinity. MHC binding to TCR is dictated by two different recognition sites: the first involves the proper self MHC/TCR interaction, is referred as the histotope-resitope recognition and is independent of the antigenic peptide, while the second involves the antigenic epitope/TCR interaction, referred as epitope-paratope recognition and depends upon the antigenic peptide loaded onto MHC (Fig. 3) . Therefore, in the context of MHC restriction, the histotope-resitope interaction will occur independently of the antigenic peptide. It can therefore be hypothesized that regardless the peptidic load of sMHC-II, this will be able to interact with TCR in a low-affinity manner, which might result in a different activation state of T-cells and different end products. Therefore, the system becomes increasingly complicated.
However, taking into consideration the overall mechanisms of the immune response, one could foresee the use of sMHC in reversing pathological conditions. Many studies demonstrate the role of sMHC in the maintenance of tolerance. Thus, one could predict that sMHC-I or sMHC-II molecules loaded with specific peptides could be used in treatment of the corresponding autoimmunity. In such cases, understanding the structure as well as the mechanisms of production, antigen loading and excretion would be extremely important. Similar reasoning can be made for all pathological conditions mentioned herein. Extensive studies and novel technological approaches are needed in order to deeply exploit sMHC molecules in diagnosis and treatment.
Conclusion
Soluble MHC molecules in serum and body fluids have a long history in the field of immunology, yet not sufficiently studied. These molecules seem to regulate the immune response by competing their surface counterparts and consequently altering signal transduction pathways evoked by T-cells upon binding to the equivalent TCR. sMHC-II have been proved to be loaded with self and tolerogenic peptides, ensuring the maintenance of self-tolerance by inducing inhibitory signals to T-cells and their products. However, it seems that depending on the stage of T-cell development/activation a different effect can be elaborated. Such complicated networks explain why sMHC molecules are hard to study and definitely define their role. However, their immunoregulatory properties and their involvement in a vast number of severe diseases make their further exploitation important.
